Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 4/20 | 0.38 |
| ▸ | JAK3 known ✓ | P52333 | 4/20 | 0.38 |
| ▸ | JAK1 known ✓ | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 known ✓ | P29597 | 2/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.38 |
| ▸ | IKBKB | O14920 | 3/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31290786 | 0.95 | IMPDH2 (0.43) | IMPDH2PIK3CAROCK2ROCK1JAK2 | |
| SCHEMBL567493 | 0.95 | IMPDH2 (0.43) | IMPDH2PIK3CAROCK2ROCK1JAK2 | |
| Sulfuric Acid SCHEMBL22129651 | 0.93 | IMPDH2 (0.43) | IMPDH2PIK3CALMNASMN1; SMN2ROCK2 | |
| Hydrochloric Acid SCHEMBL22129650 | 0.93 | IMPDH2 (0.42) | IMPDH2PIK3CAROCK2ROCK1JAK2 | |
| Bromide SCHEMBL22129647 | 0.93 | IMPDH2 (0.42) | IMPDH2PIK3CAROCK2ROCK1JAK2 | |
| SCHEMBL5217117 | 0.88 | PRKCZ (0.43) | IMPDH2PIK3CALMNASMN1; SMN2NAMPT | |
| SCHEMBL11146201 | 0.81 | NAPRT (0.48) | IMPDH2ROCK2ROCK1JAK2JAK3 | |
| SCHEMBL2263563 | 0.78 | LMNA (0.48) | LMNASMN1; SMN2 | |
| SCHEMBL30357699 | 0.78 | LMNA (0.48) | LMNASMN1; SMN2 | |
| SCHEMBL24064830 | 0.77 | IMPDH2 (0.43) | IMPDH2PIK3CAROCK2ROCK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3900724-B1 | ISOQUINOLINE SULFONYL CHLORIDE ACID ADDITION SALTS AND METHOD OF MANUFACTURE THEREOF | D WESTERN THERAPEUTICS INST INC (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-113194949-B | Isoquinoline sulfonyl chlorate addition salt and method for producing the same | 株式会社D.西医疗法研究所 | 2024-05-31 | — | — | CN | disclosed |
| US-11535595-B2 | Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2022-12-27 | — | — | US | disclosed |
| US-20210395205-A1 | ISOQUINOLINE SULFONYL CHLORIDE ACID ADDITION SALTS AND METHOD OF MANUFACTURE THEREOF | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3900724-A1 | ISOQUINOLINESULFONYL CHLORIDE ACID ADDITION SALT AND METHOD FOR PRODUCING SAME | D. Western Therapeutics Institute, Inc. (JP) | 2021-10-27 | — | — | EP | disclosed |
| CN-113194949-A | Isoquinoline sulfonyl chloric acid addition salt and preparation method thereof | 株式会社D.西医疗法研究所 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020129877-A1 | ISOQUINOLINESULFONYL CHLORIDE ACID ADDITION SALT AND METHOD FOR PRODUCING SAME | 株式会社デ・ウエスタン・セラピテクス研究所 | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535595-B2 | Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof | SQOR, TST, NOS2 | JAK2 284/4885JAK3 1993/4885JAK1 1586/4885 |
| US-20210395205-A1 | ISOQUINOLINE SULFONYL CHLORIDE ACID ADDITION SALTS AND METHOD OF MANUFACTURE THEREOF | SQOR, TST, NOS2 | JAK2 284/4885JAK3 1993/4885JAK1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.